Steering Committees, Panels, and Boards
The IAS–USA Antiretroviral Guidelines Panel was initially convened in 1995 when several advances in knowledge regarding HIV biology, monitoring, and treatment were emerging. Members are selected based on their expertise in HIV research and clinical care and serve in a voluntary capacity. The recommendations of the panel were first published in the Journal of the American Medical Association in 1996. The Guidelines are intended for developed areas where most drugs and laboratory assays are accessible. The Panel continues to update its recommendations for antiretroviral therapy for adult HIV-1 infection based on new information and drugs that are available.
The Cases on the Web (COW) Editorial Board, initially convened in 1999, is a select group of experts committed to the field of HIV care and are dedicated to teaching physicians and health care practitioners who are actively involved in the care of patients with HIV, hepatitis C virus, and other viral infections. The COW Editorial Board ensures that the program remains a relevant and useful educational tool for the IAS–USA audience.
The HIV Drug Resistance Mutations Figures and User Notes are regularly revised and disseminated by the IAS–USA Drug Resistance Mutations Group, a volunteer panel of experts, derived from the Resistance Testing Panel in 1998, focused on identifying key HIV-1 drug resistance mutations. The group strives to provide current, accurate, and unbiased information on these mutations for HIV practitioners. The mutations figures and accompanying text are published in Topics in Antiviral Medicine™ (formerly Topics in HIV Medicine®).
The Metabolic Complications Guidelines Panel, initially convened in 2000, represents international expertise in HIV-1 patient care, antiretroviral therapy, and endocrine and metabolic disorders. The Panel reviewed published results of clinical, epidemiologic, and basic science studies, data, and abstracts presented at research conferences, primarily during 1997 to 2002. The Panel also considered studies of the pathophysiology and treatment of similar metabolic abnormalities in non–HIV-1-infected persons. Emphasis was placed on results from prospective, randomized, controlled clinical trials when available.
The IAS–USA Resistance Testing Guidelines Panel, initially convened in 1997, was appointed to review for clinicians the biologic principles underlying HIV drug resistance, phenotypic and genotypic resistance assays either available or under development, and approaches using viral resistance testing for patient care. The Panel consists of persons with expertise in HIV antiretroviral drug resistance and in care of patients with HIV infection. The Resistance Testing Guidelines were last updated in 2008.